Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus

被引：1

作者：

Kaplan, Alyson ^{[1
]}

DeHaan, Elliott ^{[2
]}

Maltz, Charles ^{[1
]}

机构：

[1] New York Presbyterian, Dept Med, Div Gastroenterol & Hepatol, Weill Cornell Sch Med, New York, NY 10065 USA

[2] New York Presbyterian, Dept Med, Div Infect Dis, Weill Cornell Sch Med, New York, NY USA

来源：

ACG CASE REPORTS JOURNAL | 2021年 / 8卷 / 05期

关键词：

MONOCLONAL-ANTIBODY; HIV-1;

D O I：

10.14309/crj.0000000000000594

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Despite the decreasing morbidity associated with the human immunodeficiency virus (HIV), a large percentage of persons with HIV have at least 1 drug resistance mutation. Ibalizumab, a recently approved drug, targets multidrug-resistant HIV. We present a case of reactivation of hepatitis B after initiation of ibalizumab therapy.

引用

页数：3

共 50 条

[31] REACTIVATION OF HEPATITIS-B VIRUS IN A PREVIOUSLY IMMUNE PATIENT WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
VANDERCAM, B
CORNU, C
GALA, JL
GEUBEL, A
CAHILL, M
LAMY, ME
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1990, 9 (09) : 701 - 702
[32] Disseminated infection due to multidrug-resistant Mycobacterium bovis in a patient who was seropositive for human immunodeficiency virus
Schultsz, C
Kuijper, EJ
vanSoolingen, D
Prins, JM
CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 841 - 843
[33] 4′-ethynyl nucleoside analogs:: Potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro
Kodama, EI
Kohgo, S
Kitano, K
Machida, H
Gatanaga, H
Shigeta, S
Matsuoka, M
Ohrui, H
Mitsuya, H
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (05) : 1539 - 1546
[34] Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis
Colby, Donn J.
Kroon, Eugene
Sacdalan, Carlo
Gandhi, Monica
Grant, Robert M.
Phanuphak, Praphan
Ananworanich, Jintanat
Robb, Merlin L.
Phanuphak, Nittaya
CLINICAL INFECTIOUS DISEASES, 2018, 67 (06) : 962 - 964
[35] The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients
Mitsumoto, Fujiko
Murata, Masayuki
Ura, Kazuya
Takayama, Koji
Hiramine, Satoshi
Shimizu, Motohiro
Toyoda, Kazuhiro
Ogawa, Eiichi
Furusyo, Norihiro
Hayashi, Jun
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2015, 21 (3-4) : 264 - 271
[36] Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy
Luisa Manzano-Alonso, Maria
Castellano-Tortajada, Gregorio
WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (12) : 1531 - 1537
[37] Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy
María Luisa Manzano-Alonso
Gregorio Castellano-Tortajada
World Journal of Gastroenterology, 2011, 17 (12) : 1531 - 1537
[38] Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy
Chon, Young E.
Jin, Bora
Ahn, Sang H.
Kim, Seungtaek
Kim, Nam D.
Park, Jeon H.
Nam, Chung M.
Kim, Kyun-Hwan
Hong, Sun P.
Choi, Sung H.
Kim, Do Y.
Park, Jun Y.
Han, Kwang-Hyub
LIVER INTERNATIONAL, 2015, 35 (11) : 2370 - 2383
[39] Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus
Baran, Bulent
Soyer, Ozlem Mutluay
Ormeci, Asli Cifcibasi
Gokturk, Suut
Evirgen, Sami
Akyuz, Filiz
Karaca, Cetin
Demir, Kadir
Besisik, Fatih
Onel, Derya
Gulluoglu, Mine
Badur, Selim
Kaymakoglu, Sabahattin
LIVER INTERNATIONAL, 2015, 35 (10) : 2265 - 2274
[40] Amplification of multidrug-resistant virus by single drugs in mixed multidrug-resistant:wildtype coculture
Brenner, B
Routy, JP
Spira, B
Moisi, D
Oliveira, M
deTorio, M
Wainberg, MA
ANTIVIRAL THERAPY, 2002, 7 : S89 - S89

← 1 2 3 4 5 →